IRCT20200531047619N1招募中3 期
Evaluation of the effect of Tofacitinib drug (Iranian brand of Rhofanib drug) on clinical and laboratory symptoms in severe and resistant patients with COVID-19
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Severe illness (respiratory rate above 30 per minute, heart rate above 120 per minute and per cent reduction in peripheral oxygen saturation to less than 93%)
- •Patients resistant to existing treatments
排除标准
- •Bacterial infection is positive for the patient or procalcitonin is positive
- •The patient may have hepatitis B or hepatitis C or HIV
- •The patient has pulmonary embolism or intravascular thrombosis
- •The patient has active and inactive tuberculosis
- •The patient has diverticulitis and peptic ulcer
- •Leukocytes count less than 3500 cells / mm and hemoglobin less than 9 g / dL and neutrophils less than 1000 cells / mm3
研究者
相似试验
尚未招募
4 期
sefulness of tofacitinib in atopic dermatitisCTRI/2024/08/072026AIIMS Bhubaneswar
已完成
4 期
effectiveness of tofacitinib in moderate to severe ulcerative colitis compared to steroidCTRI/2023/09/057448Shankar Roy94
招募中
1 期
Effects of Tofacitinib on Ulcerative Colitis patientslcerative Colitis.Ulcerative colitisIRCT20181217042020N2Digestive Disease Research Institute of Tehran University of Medical Sciences40
尚未招募
Unknown
A comparison of efficacy and safety of oral tofacitinib vs methotrexate in management of moderate to severe chronic plaque psoriasisCTRI/2023/06/053443one
已完成
1 期
Tofacitinib therapy in Ulcerative Colitis patientsUlcerative colitislcerative Colitis.IRCT20181217042020N1Digestive Disease Research Institute of Tehran University of Medical Sciences50